We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Nasopharyngeal Swabs More Effective Than Saliva Tests at Detecting COVID-19

By LabMedica International staff writers
Posted on 06 Jun 2022
Print article
Image: Nostril swab may be the best way to test for COVID-19 (Photo courtesy of Unsplash)
Image: Nostril swab may be the best way to test for COVID-19 (Photo courtesy of Unsplash)

A new study has found that nasopharyngeal swabs – taken from far back inside the nostril – were more effective at detecting COVID-19 than saliva tests or swabs just inside the nostril or under the tongue. The study also found that detection rates were lower in asymptomatic patients, confirming the rationale for shortened isolation guidelines.

For the study, researchers at Cornell University (Ithaca, NY, USA) used different samples from patients: nasopharyngeal swabs, anterior nares swabs (front of the nostril), saliva and sublingual swabs (under the tongue). The researchers also collected samples from symptomatic, asymptomatic and post-symptomatic individuals – those who had recovered from illness – to better understand testing efficiency in these populations. When they compared the different sample types, the researchers found that nasopharyngeal samples provided the best rate of detection, from 92 to 100%. This is likely because the virus replicates in the nasal turbinate, the tissue structures in the uppermost portion of the nose.

Detection rates from anterior nares and saliva specimens were slightly lower, at 92 to 96% for symptomatic patients. This detection rate was lower when the samples that came from asymptomatic patients (75% to 92%). SARS-CoV-2 detection of sublingual specimens was much poorer, with detection rates of only 40 to 60% from symptomatic patient specimens and 25% to 42% from asymptomatic patient specimens. Detection rates in symptomatic, asymptomatic and post-symptomatic patients was fairly intuitive, with detection being most robust in symptomatic patients, ranging from 92 to 100%, depending on the test used. For all tests, the virus was slightly harder to detect in asymptomatic patients, at a rate of 75 to 96%. Once symptoms were resolved in post-symptomatic patients, detection was much more difficult.

The team also investigated infectivity – the level of infectious viral particles excreted in each of the sample types and from the different patient categories. As predicted, the most infectious samples came from symptomatic patients, while fewer than one-third of specimens collected from asymptomatic patients were infectious. The researchers were unable to isolate any infectious virus from post-symptomatic patient samples. This new data gives health practitioners some practical guidance.

“The study addressed the very important issue of identifying a sample type that would allow reliable detection of the virus, without significantly compromising the sensitivity of detection,” said Dr. Diego Diel, associate professor in the Department of Population Medicine and Diagnostic Sciences and director of the virology laboratory at the Animal Health Diagnostic Center, who was lead author of the study. “We were surprised at the relatively short period in which infectious virus was detected.”

Related Links:
Cornell University 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
SARS-CoV-2 Control
Gold Supplier
Auto Urinary Sediment Analyzer
Automated Hematology Analyzer
Celltac Alpha MEK-1301/1302

Print article


Molecular Diagnostics

view channel
Image: A new machine rapidly and robustly separates cancer cells from blood samples (Photo courtesy of DGIST)

Centrifugal System for Separating Circulating Tumor Cells from Blood Samples to Improve Cancer Diagnosis

Circulating tumor cells are cells that break off from cancers and are released into the blood stream. They can go on to form the seeds for new tumor formation in other parts of the body, known as metastases.... Read more


view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.